SCHEMBL7219795

SCHEMBL7219795

Nc1cc(Cl)nc(Oc2cccc3ccccc23)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.45
MAPT P10636 3/20 0.43
HTT P42858 2/20 0.43
ESRRA P11474 1/20 0.41
PIN1 Q13526 1/20 0.41
KDM1A O60341 2/20 0.41
RCOR1 Q9UKL0 1/20 0.41
SIRT2 Q8IXJ6 1/20 0.40
SIRT1 Q96EB6 1/20 0.40
SIRT3 Q9NTG7 1/20 0.40
BRAF P15056 1/20 0.40
HSP90AA1 P07900 3/20 0.39
HSP90AB1 P08238 3/20 0.39
ALDH1A1 P00352 2/20 0.39
GAA P10253 2/20 0.39
PGR P06401 1/20 0.39
PTGS1 P23219 1/20 0.39
MAPK1 P28482 1/20 0.39
HSD17B10 Q99714 1/20 0.39
HTR1B P28222 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7221959 0.77 TRPA1 (0.43) HPGDMAPTHTTPIN1KDM1A
SCHEMBL11029673 0.76 ESRRA (0.47) HPGDMAPTHTTESRRAPIN1
SCHEMBL4537266 0.76 NPC1 (0.48) HPGDHTTSIRT2SIRT1SIRT3
SCHEMBL10988253 0.74 HPGD (0.66) HPGDMAPTHTTESRRAPIN1
SCHEMBL7220480 0.72 HTR1B (0.43) HPGDMAPTHTTKDM1ARCOR1
SCHEMBL4063875 0.72 MEN1 (0.62) HPGDMAPTSIRT2SIRT1SIRT3
SCHEMBL3484572 0.72 ESRRA (0.56) HPGDESRRAPIN1KDM1ARCOR1
SCHEMBL16430768 0.72 KDM4E (0.41) PIN1ALDH1A1MAPK1KDM4E
Hydrochloric Acid SCHEMBL10884537 0.71 ESRRA (0.54) HPGDESRRAPIN1KDM1ARCOR1
SCHEMBL4688830 0.71 PIN1 (0.42) HPGDESRRAPIN1KDM1ARCOR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6573278-B2 For therapy and prophylaxis of cerebral apoplexy and craniocerebral trauma BAYER AKTIENGESELLSCHAFT (DE) 2003-06-03 US disclosed
EP-0966436-B1 ARYL SULFONAMIDES AND ANALOGUES THEREOF AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES BAYER AG (DE) 2002-12-11 EP disclosed
US-20020072529-A1 Arylsulfonamides and analogues BAYER INTELLECTUAL PROPERTY GMBH (DE) 2002-06-13 US disclosed
US-6262112-B1 1-(4,4,4-TRIFLUOROBUTYLSULPHONYLOXY)-3-(2-(HYDROXYMETHYL)INDAN -4-YLOXY)-BENZENE BAYER AKTIENGESELLSCHAFT (DE) 2001-07-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020072529-A1 Arylsulfonamides and analogues ARSA, PRSS12, SNCA HPGD 1554/4885MAPT 405/4885HTT 22/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.